A Phase III Trial of One vs. Two Years of Maintenance Olaparib, With or Without Bevacizumab, in Patients With BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy
This study looks at the best way to use maintenance therapy after chemotherapy for advanced ovarian, fallopian tube, or primary peritoneal cancer. It compares taking the targeted drug olaparib for one year versus two years, with or without the blood-vessel-blocking drug bevacizumab, to see which approach works best.
You might be eligible if you have been recently diagnosed with advanced stage III or IV epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer with specific cell types or a BRCA1/2 gene mutation. Your cancer must have also responded well to your initial platinum-based chemotherapy.
Participants will be assigned to receive specific treatments involving olaparib and potentially bevacizumab for either one or two years. You will also undergo regular check-ups, imaging scans, and routine tissue or fluid sample tests to monitor your health and how the treatment is working.
This study is currently recruiting participants at multiple locations across the United States, including sites in Alabama and Alaska. Your care team can help you find the most convenient location.
- 1Testing how long maintenance therapy needs to last after chemotherapy.
- 2Comparing one year versus two years of the targeted medication olaparib.
- 3Looking at the effects of adding the drug bevacizumab to the treatment plan.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.